BASIS OF PRESENTATION (Details) |
3 Months Ended |
---|---|
May 31, 2022
item
| |
BASIS OF PRESENTATION | |
Percentage of outstanding stock owned by the President and Chairman of the Board | 81.00% |
Number of antineoplaston drugs that have received FDA approval | 0 |